OncLive: LSAM-PTX Demonstrates Disease Control, Safety in Locally Advanced Pancreatic Cancer
OncLive: LSAM-DTX Effective and Safe in NMIBC Using Direct, Multifaceted Approach
Target Oncology: Direct and Multifaceted LSAM-DTX Treatment May Be Safe and Effective in NMIBC
JACS: Surgery is a viable treatment for pancreatic cancer patients especially after chemotherapy
Current Urology Reports: Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG Shortage
Drug Development Technology: NanOlogy Starts Enrollment in NanoDoce’s Phase I/II Trial
NanOlogy Named to BioSpace Top 20 Life Science Startups to Watch in 2019
Wuxi AppTec: Small Molecule Chemotherapy May Play a Big Role in Cancer Immunotherapy
Drug Development: Targeted Delivery of Submicron Particle Cancer Chemotherapy: Helping Shift the Immunotherapy Paradigm
Drug Delivery: NanOlogy Touts Preclinical Data for Inhaled NanoPac Cancer Drug
Boston Business Journal: NanOlogy Completes Dose Escalation Portion of Phase 2 Clinical Trial of NanoPac for Treatment of Prostate Cancer
BioCentury: Tiny Taxanes – How Nanology’s Particle Production Technology Created Submicron Chemotherapy
Drug Delivery: NanOlogy looks to transform chemotherapy with localized delivery platform
Drug Development: NanOlogy Submicron Particle Platform Transforms Systemic Chemotherapy Into Local Delivery
DermWire: NanOlogy Enrolls First Patient in Clinical Trial for Cutaneous Metastases
Houston Business Journal: NanOlogy to Update Clinical Program at BIO CEO Conference
PharmaVOICE: Next-Generation Nanomedicines
Drug Delivery Business: NanOlogy takes nanoparticle tech into Phase II trials
Clinical Leader: Trial Aims To Kill Cancer Without Chemotherapy Side Effects
DDNEWS: New Cancer Answer
Ovarian Cancer News: First Patient Enrolled in NanoPac Trial Evaluating New Anti-Cancer Treatment Delivery
Journal for Clinical Studies: NanOlogy begins NanoPac’s phase 2 study to treat ovarian cancer
Drug Delivery: NanOlogy takes nanoparticle tech into phase 2 trials.
PBR: NanOlogy begins NanoPac’s phase 2 study to treat ovarian cancer
Practical Dermatology: Update from DFB Soria on Enrollment in Phase 2 Clinical Trial of Nanoparticle Paclitaxel Ointment for AK
DFB Pharmaceuticals Forms NanOlogy & Soria for Clinical Development of Naked Nanoparticle Platform
Cancer Treatment: DFB Pharmaceuticals forms new company that could revolutionize cancer treatment
‘Bare’-ish on naked effort, Nanology unveils particle approach across cancers
DFB Pharmaceuticals Forms NanOlogy™
DFB Pharmaceuticals Forms NanOlogy™ for Clinical Development of Naked Nanoparticle Platform to Treat Cancer and Related Illnesses
